I think the last time Dr. Anderson (Ph.D., if memory serves) had Merck at “Market Perform” was back in the Fall of 2008.
As recently as the end of May of this year, he had Merck as an “Outperform”.
Here’s this morning’s news item covering it — and a bit of it:
. . . .Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group downgraded shares of Merck & Co from a “buy” rating to a “hold” rating in a research note to investors on Friday. They now have a $50.00 price target on the stock, down previously from $53.00. Separately, analysts at Credit Suisse initiated coverage on shares of Merck & Co in a research note to investors on Tuesday, October 8th. They set a “neutral” rating and a $49.00 price target on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Tuesday, October 8th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $51.09. . . .
Of course, we will — as ever — keep you apprised.